Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.45 |
| ▸ | CCR2 | P41597 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | HTR1A | P08908 | 1/20 | 0.32 |
| ▸ | DRD3 | P35462 | 1/20 | 0.32 |
| ▸ | HTR2B | P41595 | 1/20 | 0.32 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.30 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.30 |
| ▸ | KDR | P35968 | 1/20 | 0.30 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22893242 | 0.87 | HRH3 (0.47) | HRH3CCR2KCNH2CHRM2HTR1A | |
| SCHEMBL24700866 | 0.87 | HRH3 (0.47) | HRH3CCR2KCNH2CHRM2HTR1A | |
| SCHEMBL21169576 | 0.86 | HRH3 (0.36) | HRH3 | |
| SCHEMBL23473513 | 0.86 | HRH3 (0.36) | HRH3 | |
| SCHEMBL26194411 | 0.86 | HRH3 (0.46) | HRH3CCR2KCNH2CHRM2HTR1A | |
| SCHEMBL23920781 | 0.85 | HRH3 (0.43) | HRH3CCR2KCNH2CHRM2HTR1A | |
| SCHEMBL24599424 | 0.84 | HRH3 (0.42) | HRH3CCR2KCNH2 | |
| SCHEMBL25872792 | 0.83 | HRH3 (0.44) | HRH3CCR2KCNH2CHRM2HTR1A | |
| SCHEMBL24256708 | 0.83 | HRH3 (0.44) | HRH3CCR2KCNH2CHRM2HTR1A | |
| SCHEMBL20980172 | 0.82 | HRH3 (0.43) | HRH3CCR2KCNH2CHRM2HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230271965-A1 | BICYCLIC HETEROARENES AND METHODS OF THEIR USE | YUMANITY THERAPEUTICS, INC. | 2023-08-31 | — | — | US | disclosed |
| US-20230140941-A1 | NON-ATP/CATALYTIC SITE P38 MITOGEN ACTIVATED PROTEIN KINASE INHIBITORS | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2023-05-11 | — | — | US | disclosed |
| US-11319323-B2 | Substituted pyrazolo[4,3-H]quinazolines as protein kinase inhibitors | SHENGKE PHARMACEUTICALS (JIANGSU) LTD. (CN) | 2022-05-03 | — | — | US | disclosed |
| US-20210379084-A1 | INHIBITORS OF GLUCOCORTICOID RECEPTOR | ORIC PHARMACEUTICALS, INC. | 2021-12-09 | — | — | US | disclosed |
| US-11110103-B2 | Inhibitors of glucocorticoid receptor | ORIC PHARMACEUTICALS, INC. (US) | 2021-09-07 | — | — | US | disclosed |
| US-20210023095-A1 | INHIBITORS OF GLUCOCORTICOID RECEPTOR | ORIC PHARMACEUTICALS, INC. | 2021-01-28 | — | — | US | disclosed |
| US-20210017219-A1 | INHIBITORS OF GLUCOCORTICOID RECEPTOR | ORIC PHARMACEUTICALS, INC. | 2021-01-21 | — | — | US | disclosed |
| US-20200291058-A1 | INHIBITORS OF GLUCOCORTICOID RECEPTOR | ORIC PHARMACEUTICALS, INC. | 2020-09-17 | — | — | US | disclosed |
| US-10682358-B2 | Substituted 2, 3-dihydro-1H-inden-1-one retinoic acid-related orphan nuclear receptor antagonists for treating multiple sclerosis | ARRIEN PHARMACEUTICALS LLC (US) | 2020-06-16 | — | — | US | disclosed |
| US-20190209574-A1 | SUBSTITUTED 2, 3-DIHYDRO-1H-INDEN-1-ONE RETINOIC ACID-RELATED ORPHAN NUCLEAR RECEPTOR ANTAGONISTS FOR TREATING MULTIPLE SCLEROSIS | ARRIEN PHARMACEUTICALS LLC (US) | 2019-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230140941-A1 | NON-ATP/CATALYTIC SITE P38 MITOGEN ACTIVATED PROTEIN KINASE INHIBITORS | MAPK1, MAPK8, MAPK4 | HRH3 3499/4885CCR2 1186/4885KCNH2 4580/4885 |
| US-10682358-B2 | Substituted 2, 3-dihydro-1H-inden-1-one retinoic acid-related orphan nuclear receptor antagonists for treating multiple sclerosis | RORA, RORB, RORC | HRH3 611/4885CCR2 334/4885KCNH2 3505/4885 |
| US-20210017219-A1 | INHIBITORS OF GLUCOCORTICOID RECEPTOR | NR3C1, NR3C2, MC2R | HRH3 789/4885CCR2 1239/4885KCNH2 4579/4885 |
| US-20230271965-A1 | BICYCLIC HETEROARENES AND METHODS OF THEIR USE | NLN, GRIN2C, BCHE | HRH3 984/4885CCR2 3779/4885KCNH2 2132/4885 |
| US-20210023095-A1 | INHIBITORS OF GLUCOCORTICOID RECEPTOR | NR3C1, NR3C2, MC2R | HRH3 841/4885CCR2 1372/4885KCNH2 4479/4885 |
| US-20210379084-A1 | INHIBITORS OF GLUCOCORTICOID RECEPTOR | NR3C1, NR3C2, MC2R | HRH3 841/4885CCR2 1372/4885KCNH2 4479/4885 |
| US-11319323-B2 | Substituted pyrazolo[4,3-H]quinazolines as protein kinase inhibitors | CDK1, CDK2, CDK3 | HRH3 1792/4885CCR2 3009/4885KCNH2 2018/4885 |
| US-20190209574-A1 | SUBSTITUTED 2, 3-DIHYDRO-1H-INDEN-1-ONE RETINOIC ACID-RELATED ORPHAN NUCLEAR RECEPTOR ANTAGONISTS FOR TREATING MULTIPLE SCLEROSIS | RORA, RORB, RORC | HRH3 611/4885CCR2 334/4885KCNH2 3505/4885 |
| US-20200291058-A1 | INHIBITORS OF GLUCOCORTICOID RECEPTOR | NR3C1, NR3C2, MC2R | HRH3 789/4885CCR2 1239/4885KCNH2 4579/4885 |
| US-11110103-B2 | Inhibitors of glucocorticoid receptor | NR3C1, NR3C2, MC2R | HRH3 841/4885CCR2 1372/4885KCNH2 4479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.